Myopathy in scleroderma, its identification, prevalence, and treatment: Lessons learned from cohort studies

Research output: Contribution to journalArticle

Abstract

PURPOSE OF REVIEW: This review discusses the characterization of myopathy in scleroderma with a focus on new developments in imaging, biomarkers, and therapy, and details several current reports and several seminal reports prior to 2012. RECENT FINDINGS: In the past year, studies have shown that MRI techniques highlight the importance of muscle edema in scleroderma, and that aldolase may be a useful biomarker to predict incident myopathy. When compared to studies preceding 2012, both the current and prior reports too often fail to account for the full spectrum of muscle disease in scleroderma. There remain no uniform classification criteria that are routinely integrated into clinical research reports. Thus, important questions remain to be answered, including risk factors for developing myopathy, optimal screening and diagnostic strategies, and efficacious therapies. But, just as important is the priority to systematically define what the true entity(ies) of myopathy is in scleroderma. SUMMARY: Scleroderma myopathy is a heterogeneous group of muscle disorders among patients with underlying scleroderma which requires robust studies to clarify the full spectrum of disease.

Original languageEnglish (US)
Pages (from-to)124-130
Number of pages7
JournalCurrent Opinion in Rheumatology
Volume26
Issue number2
DOIs
StatePublished - Mar 2014

Fingerprint

Muscular Diseases
Cohort Studies
Therapeutics
Biomarkers
Muscles
Fructose-Bisphosphate Aldolase
Edema

Keywords

  • epidemiology
  • myopathy
  • myositis
  • scleroderma

ASJC Scopus subject areas

  • Rheumatology

Cite this

@article{7ce4c94dac074eeab3fd6dffbb409691,
title = "Myopathy in scleroderma, its identification, prevalence, and treatment: Lessons learned from cohort studies",
abstract = "PURPOSE OF REVIEW: This review discusses the characterization of myopathy in scleroderma with a focus on new developments in imaging, biomarkers, and therapy, and details several current reports and several seminal reports prior to 2012. RECENT FINDINGS: In the past year, studies have shown that MRI techniques highlight the importance of muscle edema in scleroderma, and that aldolase may be a useful biomarker to predict incident myopathy. When compared to studies preceding 2012, both the current and prior reports too often fail to account for the full spectrum of muscle disease in scleroderma. There remain no uniform classification criteria that are routinely integrated into clinical research reports. Thus, important questions remain to be answered, including risk factors for developing myopathy, optimal screening and diagnostic strategies, and efficacious therapies. But, just as important is the priority to systematically define what the true entity(ies) of myopathy is in scleroderma. SUMMARY: Scleroderma myopathy is a heterogeneous group of muscle disorders among patients with underlying scleroderma which requires robust studies to clarify the full spectrum of disease.",
keywords = "epidemiology, myopathy, myositis, scleroderma",
author = "Julie Paik and Mammen, {Andrew L.} and Fredrick Wigley and Allan Gelber",
year = "2014",
month = "3",
doi = "10.1097/BOR.0000000000000024",
language = "English (US)",
volume = "26",
pages = "124--130",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Myopathy in scleroderma, its identification, prevalence, and treatment

T2 - Lessons learned from cohort studies

AU - Paik, Julie

AU - Mammen, Andrew L.

AU - Wigley, Fredrick

AU - Gelber, Allan

PY - 2014/3

Y1 - 2014/3

N2 - PURPOSE OF REVIEW: This review discusses the characterization of myopathy in scleroderma with a focus on new developments in imaging, biomarkers, and therapy, and details several current reports and several seminal reports prior to 2012. RECENT FINDINGS: In the past year, studies have shown that MRI techniques highlight the importance of muscle edema in scleroderma, and that aldolase may be a useful biomarker to predict incident myopathy. When compared to studies preceding 2012, both the current and prior reports too often fail to account for the full spectrum of muscle disease in scleroderma. There remain no uniform classification criteria that are routinely integrated into clinical research reports. Thus, important questions remain to be answered, including risk factors for developing myopathy, optimal screening and diagnostic strategies, and efficacious therapies. But, just as important is the priority to systematically define what the true entity(ies) of myopathy is in scleroderma. SUMMARY: Scleroderma myopathy is a heterogeneous group of muscle disorders among patients with underlying scleroderma which requires robust studies to clarify the full spectrum of disease.

AB - PURPOSE OF REVIEW: This review discusses the characterization of myopathy in scleroderma with a focus on new developments in imaging, biomarkers, and therapy, and details several current reports and several seminal reports prior to 2012. RECENT FINDINGS: In the past year, studies have shown that MRI techniques highlight the importance of muscle edema in scleroderma, and that aldolase may be a useful biomarker to predict incident myopathy. When compared to studies preceding 2012, both the current and prior reports too often fail to account for the full spectrum of muscle disease in scleroderma. There remain no uniform classification criteria that are routinely integrated into clinical research reports. Thus, important questions remain to be answered, including risk factors for developing myopathy, optimal screening and diagnostic strategies, and efficacious therapies. But, just as important is the priority to systematically define what the true entity(ies) of myopathy is in scleroderma. SUMMARY: Scleroderma myopathy is a heterogeneous group of muscle disorders among patients with underlying scleroderma which requires robust studies to clarify the full spectrum of disease.

KW - epidemiology

KW - myopathy

KW - myositis

KW - scleroderma

UR - http://www.scopus.com/inward/record.url?scp=84894069692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894069692&partnerID=8YFLogxK

U2 - 10.1097/BOR.0000000000000024

DO - 10.1097/BOR.0000000000000024

M3 - Article

C2 - 24419752

AN - SCOPUS:84894069692

VL - 26

SP - 124

EP - 130

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 2

ER -